Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma
Authors:
- Neeraj JainNJNeeraj Jain
- Keenan HartertKHKeenan Hartert
- Saber TadrosSTSaber Tadros
- Warren FiskusWFWarren Fiskus
- Ondrej HavranekOHOndrej Havranek
- Man-Chun John MaMMMan-Chun John Ma
- Alyssa BouskaABAlyssa Bouska
- Tayla HeavicanTHTayla Heavican
- Dhiraj KumarDKDhiraj Kumar
- Qing DengQDQing Deng
- Dalia MooreDMDalia Moore
- Christine PakCPChristine Pak
Preprint
Abstract
The activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) is characterized by the chronic activation of signaling initiated by immunoglobulin-μ (IgM). By analyzing DNA copy profiles of 1,000 DLBCLs, we identified gains of 18q21.2 as the most frequent genetic alteration in ABC-like DLBCL. We show that these alterations target the TCF4 (E2-2) transcription factor, and that over-expression of TCF4 leads to its occupancy on immunoglobulin gene enhancers and increased expression of IgM at the transcript and protein level. The TCF4 gene is one of the top BRD4-regulated genes in DLBCL. Using a BET proteolysis-targeting chimera (PROTAC) we show that TCF4 and IgM expression can be extinguished, and ABC-like DLBCL cells can be killed in vitro and in vivo . This highlights a novel genetic mechanism for promoting immunoglobulin signaling in ABC-like DLBCL and provides a functional rationale for the use of BET inhibitors in this disease.Keywords
All Related Versions
- Published version: Science Translational Medicine, 11 (497).
This publication has 131 references indexed in Scilit:
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphomaLeukemia, 2011
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Stromal Gene Signatures in Large-B-Cell LymphomasNew England Journal of Medicine, 2008
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell LymphomaScience, 2008
- How I treat patients with diffuse large B-cell lymphomaBlood, 2007
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000